Zuellig Pharma 从礼来公司收购了 Cialis® 和 Alimta®，用于选定的东盟市场，以加强其医疗保健作用并扩大商业影响力。 Zuellig Pharma acquires Cialis® and Alimta® from Eli Lilly for select ASEAN markets to bolster its healthcare role and expand commercial presence.

Zuellig Pharma 是一家亚洲大型医疗保健公司，已从礼来公司收购了 Cialis®（他达拉非）和 Alimta®（培美曲塞），用于指定的东盟市场。 Zuellig Pharma, a major healthcare company in Asia, has acquired Cialis® (Tadalafil) and Alimta® (Pemetrexed) from Eli Lilly and Company for select ASEAN markets. 收购的品牌 Alimta®（治疗非小细胞肺癌和恶性胸膜间皮瘤的化疗药物）和 Cialis®（治疗勃起功能障碍的领先男性保健产品）将由 Zuellig Pharma 的商业部门 ZP Therapeutics 推广，在各自的市场。 The acquired brands, Alimta® (a chemotherapy drug for non-small cell lung cancer and malignant pleural mesothelioma) and Cialis® (a leading men's health product for erectile dysfunction), will be promoted by ZP Therapeutics, the commercial division of Zuellig Pharma, in the respective markets. 此次收购旨在加强 Zuellig Pharma 在医疗保健领域的作用并扩大其在该地区的商业影响力。 This acquisition aims to strengthen Zuellig Pharma's role in healthcare and expand its commercial presence in the region.